Skip to main content

Breyanzi Disease Interactions

There are 2 disease interactions with Breyanzi (lisocabtagene maraleucel).

Major

Lisocabtagene (applies to Breyanzi) infection

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Lisocabtagene maraleucel should not be administered to patients with active infection or inflammatory disorders. Monitor patients for signs or symptoms of infection and treat appropriately.

References

  1. (2021) "Product Information. Breyanzi (lisocabtagene maraleucel)." Bristol-Myers Squibb
Moderate

Lisocabtagene maraleucel (applies to Breyanzi) hepatitis B reactivation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis

Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells, such as lisocabtagene maraleucel. Screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing is advised. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines.

References

  1. (2021) "Product Information. Breyanzi (lisocabtagene maraleucel)." Bristol-Myers Squibb

Breyanzi drug interactions

There are 198 drug interactions with Breyanzi (lisocabtagene maraleucel).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer